$PBIO Pressure BioSciences Leveraging Strong FY202
Post# of 1354
(Total Views: 200)
Posted On: 04/05/2022 11:50:26 AM
$PBIO Pressure BioSciences Leveraging Strong FY2021 Operational and Financial Successes, Worldwide Customer Base, Substantial IP Estate, and Three Powerful Technology Platforms to Accelerate Strategic Company Transformation in 2022
https://www.accesswire.com/696078/pressure-bi...on-in-2022
Q4 and FY2021 Total Revenue Increased 91% and 64% Respectfully Over Same Periods in 2020;
PCT, BaroFold, and PBI Agrochem Groups Scored Important Gains in 2021;
UST Platform Achieved Critical 2021 Goals - Discussions Ongoing with Key Leaders in Multiple Markets
Investor Conference Call Scheduled for Tuesday April 5 at 4:30 PM ET
SOUTH EASTON, MA / ACCESSWIRE / April 5, 2022 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotherapeutics, nutraceuticals, cosmetics, agrochem, food & beverage, and other industries, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, provided a business update, and offered guidance on the Company's strategic changes and growth acceleration planned for FY 2022.
Over the past 15 years, PBI has acquired a wealth of knowledge and experience in the use of pressure to create remarkable results in a variety of commercially-attractive areas using the Company's three enabling technology platforms: Pressure Cycling Technology ("PCT" , BaroFold™, and Ultra Shear Technology™ ("UST™" .
Jeffrey N. Peterson, Chairman of the PBI Board, set the stage for PBI's exciting future: "The PCT and BaroFold technologies have provided important early opportunities for commercial traction, as PBI forged scientific understanding and acceptance for its high-pressure platforms. Building on multiple peer-reviewed opinion leader scientific articles and presentations, accelerating instrument installations, and expanding paid research projects, these platforms are expected to generate important sales growth in 2022 and beyond. In addition, we believe the UST platform is opening up a new, game-changing growth trajectory with its promise for revolutionizing massive global markets from pharmaceuticals, nutraceuticals, cosmetics, agrochem, food/beverage processing, and more."
Richard T. Schumacher, President and CEO of PBI, continued the thought: "As we evaluated the prospective commercial successes for our technologies and products, UST singularly stood out. After extensive development efforts and due diligence, we came to understand that the proprietary UST platform is a disruptive technology with revenue potential that we believe can be transformative for PBI and the major markets it will serve. We have consequently focused the majority of the PBI Team's 2021 efforts on UST development and on the commercial introduction and acceleration for UST in 2022."
Mr. John Hollister joined the PBI Team as Director of Marketing and Sales in 2020. He came to PBI with broad experience in leading commercialization of major products in large companies like SmithKline (now GSK) and Amgen, as well as in the start-up world for the previous 17 years. His diverse experience in successfully developing and leading marketing programs (including initial product commercialization) with both large and modest budgets will be pivotal for PBI, as he leads our UST commercialization program. He is already driving the planning and execution of critical partnering and initial commercialization strategies in order to build rapid and robust customer adoption and to accelerate growth in 2022.
Mr. Hollister said: "The amazing PBI Team has spent years becoming experts in how to safely capture and utilize pressure to improve existing methods in research and pharmaceutical manufacturing. With the 2022 commercialization of UST, PBI will introduce to the world the full potential of what pressure can do in a variety of large and growing markets. The coming months will be a very exciting time for PBI, our customers, and for the users of their UST-processed products."
Financial Results: Q4 2021 vs. Q4 2020
Total revenue for Q4 2021 was $315,199 compared to $164,702 for the same period in 2020, a 91% increase. This increase was primarily due to our double-digit growth in products and services.
Sales of instruments increased to $115,784 in Q4 2021 compared to $0 in Q4 2020.
Consumable sales were $82,680 for Q4 2021 compared to $48,651 for the same period in 2020, a 70% increase.
Operating loss for Q4 2021 was $1,221,148 compared to $1,041,293 for the same period in 2020, primarily due to increases in general and administrative expense.
Loss per common share - basic & diluted - decreased to $(0.48) for Q4 2021 from $(1.19) for Q4 2020.
Financial Results: FY2021 vs. FY2020
Total revenue for FY 2021 was $2,002,365 compared to $1,220,591 for FY2020, a 64% increase. This increase was primarily due to our growth in products and services.
Sales of instruments increased to $1,105,268 for FY 2021 compared to $568,457 for FY 2020, an increase of 94%
Consumable sales were $274,108 for the year ended December 31, 2021 compared to $204,889 for the same period in 2020, an increase of $69,219 or 34%.
Operating loss for FY 2021 was $4,185,147 compared to $4,585,787 for FY 2020. This decrease was primarily due to increases in total revenue.
Loss per common share - basic and diluted - decreased to $(3.42) for FY2021 from $(5.32) for the 2020 fiscal year.
Operational & Technical Highlights (2021/2022)
Solid progress reported on FY 2022 key goals.
Ohio State installs/commissions BaroShear MAX UST processing equipment at renowned Food Pilot Plant.
UST processing achieves 18-month stability of CBD oil nanoemulsion.
Five UST patents awarded, including two for critical nanogap valve.
Strong demand observed for our BaroFold protein refolding platform specialty testing services.
UST successfully transforms Neem Oil into a novel highly potent nanoemulsion for effective agrochem use.
UST demo and manufacturing sites (Fall 2022) named: Boston, MA and Mountain View, CA.
PBI establishes wholly-owned PBI Agrochem subsidiary.
UST platform successfully processes one of the world's most potent antioxidants: Astaxanthin.
PBI and Ohio State University announce partnership in the formation of a food industry consortium to advance commercialization of the UST platform.
Earnings Call and Business Update
The Company will hold an Earnings Conference Call and Business Update at 4:30 PM ET on Tuesday, April 5, 2022. To attend this teleconference via telephone, Dial-in: (888) 506-0062 (North America), (973) 528-0011 (International). Verbal Passcode: 648452 or say Pressure BioSciences Fourth Quarter and Fiscal Year 2021 Financial Call. Replay Number (877) 481-4010; (919) 882-2331 (International). Replay Passcode: 45153. Teleconference Replay Available for 30 days.
https://www.accesswire.com/696078/pressure-bi...on-in-2022
Q4 and FY2021 Total Revenue Increased 91% and 64% Respectfully Over Same Periods in 2020;
PCT, BaroFold, and PBI Agrochem Groups Scored Important Gains in 2021;
UST Platform Achieved Critical 2021 Goals - Discussions Ongoing with Key Leaders in Multiple Markets
Investor Conference Call Scheduled for Tuesday April 5 at 4:30 PM ET
SOUTH EASTON, MA / ACCESSWIRE / April 5, 2022 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" or the "Company" , a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotherapeutics, nutraceuticals, cosmetics, agrochem, food & beverage, and other industries, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, provided a business update, and offered guidance on the Company's strategic changes and growth acceleration planned for FY 2022. Over the past 15 years, PBI has acquired a wealth of knowledge and experience in the use of pressure to create remarkable results in a variety of commercially-attractive areas using the Company's three enabling technology platforms: Pressure Cycling Technology ("PCT"
, BaroFold™, and Ultra Shear Technology™ ("UST™" . Jeffrey N. Peterson, Chairman of the PBI Board, set the stage for PBI's exciting future: "The PCT and BaroFold technologies have provided important early opportunities for commercial traction, as PBI forged scientific understanding and acceptance for its high-pressure platforms. Building on multiple peer-reviewed opinion leader scientific articles and presentations, accelerating instrument installations, and expanding paid research projects, these platforms are expected to generate important sales growth in 2022 and beyond. In addition, we believe the UST platform is opening up a new, game-changing growth trajectory with its promise for revolutionizing massive global markets from pharmaceuticals, nutraceuticals, cosmetics, agrochem, food/beverage processing, and more."
Richard T. Schumacher, President and CEO of PBI, continued the thought: "As we evaluated the prospective commercial successes for our technologies and products, UST singularly stood out. After extensive development efforts and due diligence, we came to understand that the proprietary UST platform is a disruptive technology with revenue potential that we believe can be transformative for PBI and the major markets it will serve. We have consequently focused the majority of the PBI Team's 2021 efforts on UST development and on the commercial introduction and acceleration for UST in 2022."
Mr. John Hollister joined the PBI Team as Director of Marketing and Sales in 2020. He came to PBI with broad experience in leading commercialization of major products in large companies like SmithKline (now GSK) and Amgen, as well as in the start-up world for the previous 17 years. His diverse experience in successfully developing and leading marketing programs (including initial product commercialization) with both large and modest budgets will be pivotal for PBI, as he leads our UST commercialization program. He is already driving the planning and execution of critical partnering and initial commercialization strategies in order to build rapid and robust customer adoption and to accelerate growth in 2022.
Mr. Hollister said: "The amazing PBI Team has spent years becoming experts in how to safely capture and utilize pressure to improve existing methods in research and pharmaceutical manufacturing. With the 2022 commercialization of UST, PBI will introduce to the world the full potential of what pressure can do in a variety of large and growing markets. The coming months will be a very exciting time for PBI, our customers, and for the users of their UST-processed products."
Financial Results: Q4 2021 vs. Q4 2020
Total revenue for Q4 2021 was $315,199 compared to $164,702 for the same period in 2020, a 91% increase. This increase was primarily due to our double-digit growth in products and services.
Sales of instruments increased to $115,784 in Q4 2021 compared to $0 in Q4 2020.
Consumable sales were $82,680 for Q4 2021 compared to $48,651 for the same period in 2020, a 70% increase.
Operating loss for Q4 2021 was $1,221,148 compared to $1,041,293 for the same period in 2020, primarily due to increases in general and administrative expense.
Loss per common share - basic & diluted - decreased to $(0.48) for Q4 2021 from $(1.19) for Q4 2020.
Financial Results: FY2021 vs. FY2020
Total revenue for FY 2021 was $2,002,365 compared to $1,220,591 for FY2020, a 64% increase. This increase was primarily due to our growth in products and services.
Sales of instruments increased to $1,105,268 for FY 2021 compared to $568,457 for FY 2020, an increase of 94%
Consumable sales were $274,108 for the year ended December 31, 2021 compared to $204,889 for the same period in 2020, an increase of $69,219 or 34%.
Operating loss for FY 2021 was $4,185,147 compared to $4,585,787 for FY 2020. This decrease was primarily due to increases in total revenue.
Loss per common share - basic and diluted - decreased to $(3.42) for FY2021 from $(5.32) for the 2020 fiscal year.
Operational & Technical Highlights (2021/2022)
Solid progress reported on FY 2022 key goals.
Ohio State installs/commissions BaroShear MAX UST processing equipment at renowned Food Pilot Plant.
UST processing achieves 18-month stability of CBD oil nanoemulsion.
Five UST patents awarded, including two for critical nanogap valve.
Strong demand observed for our BaroFold protein refolding platform specialty testing services.
UST successfully transforms Neem Oil into a novel highly potent nanoemulsion for effective agrochem use.
UST demo and manufacturing sites (Fall 2022) named: Boston, MA and Mountain View, CA.
PBI establishes wholly-owned PBI Agrochem subsidiary.
UST platform successfully processes one of the world's most potent antioxidants: Astaxanthin.
PBI and Ohio State University announce partnership in the formation of a food industry consortium to advance commercialization of the UST platform.
Earnings Call and Business Update
The Company will hold an Earnings Conference Call and Business Update at 4:30 PM ET on Tuesday, April 5, 2022. To attend this teleconference via telephone, Dial-in: (888) 506-0062 (North America), (973) 528-0011 (International). Verbal Passcode: 648452 or say Pressure BioSciences Fourth Quarter and Fiscal Year 2021 Financial Call. Replay Number (877) 481-4010; (919) 882-2331 (International). Replay Passcode: 45153. Teleconference Replay Available for 30 days.
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼